Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose IL-2 Plus Pembrolizumab in Stage IV NSCLC
NCT05493566Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aldesleukin in non-small cell lung cancer (NSCLC), sponsored by Emory University. Primary endpoint: Immune Response To Combination IL-2 and Pembrolizumab at 18 weeks. Started Nov 2022; status: recruiting.
02
Drugs
aldesleukin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05493566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05493566.